Cetia connects patients, carers, and clinical teams around continuous cardiovascular monitoring — from hypertension to heart failure and AFib — so preventable harm is caught early, medication is tracked, and no one falls through the gap.
It's silent. It's slow. And the current system is not built to catch it — especially for the patients most likely to be left behind.
of adults in England have hypertension — a third of those are undiagnosed
of young men with hypertension don't know they have it
men aged 55–64 living with undiagnosed hypertension — the single largest group
annual NHS cost — most of it avoidable with earlier detection and better management
Source: ONS, Risk factors for undiagnosed high blood pressure in England, 2015–2019 (Health Survey for England / NHS Digital)
A single blood pressure reading tells you about that day. What matters most is what your heart is doing over time. At different times of day. Without the stress of being at the clinic. Trends while you're taking your medication.
GPs know this. NICE guidelines now recommend home monitoring as the standard for diagnosis and management. But the infrastructure to collect, interpret, and act on that data at scale — without creating more work for already stretched clinical teams — doesn't yet exist.
Cetia is built to close that gap.
adults in England are living with high blood pressure and don't know it. Many are younger, feel well, and have no reason to suspect anything is wrong. The system only finds them when something goes wrong. Cetia finds them sooner.
ONS · Health Survey for England 2015–2019
Whether you're a patient logging your first reading, a carer supporting someone you love, or a clinician managing a hypertension list — Cetia is designed for how you actually work.
Enter your reading manually or photograph your monitor — Cetia reads it automatically. No typing required. Works offline. Will be available in 20 languages.
Every reading comes with plain-language context, not just numbers. Your 7-day average. How it compares to last week. What to do if it's elevated — and when to call your GP.
Log when you take your medication — and when you don't. Missed doses, side effects, stopping and restarting. This context is as important as the reading itself.
Invite a family member or carer to your care circle. They can see your readings, receive alerts, and support you — without being overwhelmed with clinical detail.
Today's reading · 08:14
Pulse 71 bpm · Best of 3
Lower than your average last week of 134/86. Your 30-day trend is improving. Keep going.
Cetia is a regulated medical device designed for the NHS environment — its systems, its standards, and its patients. Not a consumer wellness app adapted for clinical use.
Regulated medical device under UK MDR 2002. UKCA mark regulatory pathway in progress.
Data Security & Protection Toolkit compliant. UK GDPR and NHS data standards met.
Integration pathway with SystmOne, EMIS, and NHS AHDS. Readings flow into clinical records without manual entry. QOF/QUAF reporting support included.
Full accessibility compliance. Will be available in 20 languages including Welsh, Urdu, Punjabi, and Polish with RTL support.
“At home BP monitoring is a top-priority clinical need — and a daily workflow pain. We get readings by phone call, then manually type them into EMIS. That data is often lost.”
GP · Primary Care · East Midlands
“NICE guidelines are now a forcing function — home readings are preferred, but the infrastructure to act on them doesn't exist in primary care.”
GP · South East England
“Longitudinal home data could help us make better and faster decisions. We see complex patients, but we can't see the data-driven picture between visits.”
Cardiologist Consultant · Secondary Care
NICE guidelines recommend ambulatory or home blood pressure monitoring as the standard for hypertension diagnosis and management. Cetia supports clinicians in delivering exactly this — without adding to their workload.
The founding clinical advisory board spans the full care pathway: the patient voice and lived experience of cardiovascular disease, primary care management of hypertension at scale, and secondary care for complex cases and specialist cardiovascular outcomes.
Trial co-design is underway with our advisory board to generate the evidence base required for full NHS commissioning. If you are a GP practice, PCN, or NHS trust interested in participating, we want to hear from you.
Cardiovascular disease is the leading cause of premature death in the UK — and its burden falls unequally. People from South Asian and Black communities face significantly elevated CVD risk, often compounded by systemic barriers to diagnosis and treatment. Women are underrepresented in the clinical research that underpins the guidelines clinicians use today. Patients in more deprived areas, those with lower health literacy, and those whose first language is not English face additional friction at every step of the care pathway.
Cetia's long-term mission extends beyond managing diagnosed hypertension. We are building the longitudinal home monitoring dataset that the NHS needs: one that captures blood pressure trends across the whole population — not just those who already engage regularly with primary care. Data that is rich enough, and representative enough, to power the next generation of cardiovascular AI — models trained on the people most likely to be left behind by existing ones.
Equitable access is a specification requirement, not a feature. Cetia will be available in 20 languages, with WCAG 2.1 AA accessibility, offline-first design, and a patient experience built for people with low health literacy — because those are the patients who need it most.
of men aged 16–24 with hypertension are undiagnosed. They feel well. They have no reason to check. The system doesn't find them until it's too late.
ONS · Health Survey for England 2015–2019
higher risk of heart failure for people of South Asian heritage in the UK, with hypertension as the leading modifiable risk factor.
British Heart Foundation · CVD Statistics 2023
of cardiovascular disease deaths in women occur without a prior CVD diagnosis. Women are underrepresented in clinical trials and their symptoms are less likely to be recognised.
British Heart Foundation · Women and CVD 2023
Cetia is in active development with NHS clinical partners. Get in touch about a pilot, or sign in to your existing account.
Photo by Xavier Mouton Photographie on Unsplash